

EDITORIAL

Open Access



Studies on immune regulation for allogeneic iPSC-based transplantation

Ken-ichiro Seino*

For allogeneic transplantation, immune regulation is critical, and the same is true for iPSC cell-based cell and tissue transplantation. Since the first report of iPSC cells in 2006, research has been conducted mainly on induction of differentiation into various functional cells for application to cell and tissue transplantation. Meanwhile, research on immune regulation seems to have been put on the back burner. However, nearly 15 years have passed since the invention of iPSC cells, and light is finally being shed on issues related to immunity. In this context, research groups, mainly in Japan, have been studying this issue in recent years.

Kawamoto et al. of Kyoto University examined the possibility of graft injury by NK cells occurring in the HLA-homo state [1]. They showed a possible method of suppressing graft injury by NK cells using HLA-C.

Kaneko et al. of Kyoto University reported on gene editing technology to prevent the expression of HLA in iPSC cells, describing not only the knockout of HLA but also the expression of HLA-E and CD47 to control NK cells [2].

Matsumoto et al. of Kyoto University summarized immune regulation in cardiac regenerative medicine using iPSC cells [3]. They also discuss immunomodulation methods using activated Tregs and MSCs.

Finally, Seino et al. of Hokkaido University comprehensively reviewed immunoregulatory methods in iPSC cell-based transplantation medicine [4]. In particular, they showed the mechanism of immune response when HLA-matched iPSC cells are used and summarized the

methods of controlling the immune response, from drug-based methods to cell-based methods, and genetic modification.

In organ transplantation, studies on immune tolerance have been conducted, in which grafts remain viable after discontinuation of immunosuppressive drugs. It has been shown that immune tolerance can be induced by means of molecular targeted therapy targeting molecules expressed on immune cells or by means of cell therapy using donor or recipient cells such as bone marrow. This has been achieved not only at the level of animal studies but also in the clinical setting, and such research directions should be important for iPSC cell-based transplantation as well.

I hope that the progress of these studies will lead to safe transplantation medicine using allogeneic iPSC cells and the development of this field.

Author's contributions

The author read and approved the final manuscript.

Declarations

Competing interests

The author declares no competing interests.

Received: 16 November 2022 Accepted: 15 December 2022

Published online: 30 December 2022

References

1. Masuda K, Kawamoto H. *Inflammation and Regeneration*. 2021;41:2.
2. Koga K, Wang B, Kaneko S. *Inflammation and Regeneration*. 2020;40:23.
3. Murata K, Ikegawa M, Minatoya K, Matsumoto H. *Inflammation and Regeneration*. 2020;40:36.
4. Otsuka R, Wada H, Murata T, Seino K-i. *Inflammation and Regeneration*. 2020;40:12.

*Correspondence: seino@igm.hokudai.ac.jp

Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

